Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965064 | 0.87 | TP53 (0.41) | MTNR1AMTNR1BTP53MEN1KMT2A | |
| SCHEMBL5115435 | 0.87 | KMO (0.38) | TP53KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL962358 | 0.85 | CA2 (0.45) | MTNR1AMTNR1BTP53FABP4MEN1 | |
| SCHEMBL5112090 | 0.85 | PHGDH (0.40) | MTNR1AMTNR1BTP53LMNA | |
| SCHEMBL5119374 | 0.84 | CDC7 (0.35) | ALDH1A1MCL1 | |
| SCHEMBL962203 | 0.81 | MTNR1A (0.35) | MTNR1AMTNR1BTP53FABP4MEN1 | |
| SCHEMBL4570493 | 0.81 | PHGDH (0.36) | TP53MEN1KMT2AMCL1 | |
| SCHEMBL5121186 | 0.81 | KDM4E (0.37) | FABP4MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4553762 | 0.78 | AGTR2 (0.37) | MCL1 | |
| SCHEMBL5117304 | 0.77 | ENPP3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | MTNR1A 310/4885MTNR1B 243/4885TP53 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.